Objective: To investigate the level of serum microRNA-609 and its clinical prognostic value in patients with thalassemia.
Methods: One hundred and twenty-seven patients with thalassemia treated in our hospital from April 2017 to April 2018 were selected, 100 healthy persons were selected as control group. The changes of miR-609 were analyzed by RT-PCR, the relationship between miR-609 and clinical indicators of thalassemia was analyzed, and the prognostic risk factors of thalassemia were evaluated by multivariate logistic regression analysis.
Results: The relative expression level of miR-609 in thalassemia patients was 3.17±0.24, which was significantly higher than that in control group (P<0.05). The levels of ALT, Plt and MCH in patients with high expression of miR-609 were significantly higher than those in patients with low expression of miR-609 (P<0.05). The levels of Hb and sICAM-1 in patients with high expression of miR-609 were significantly lower than those in patients with low expression of miR-609 (P<0.05). There was no correlation between the level of miR-609 and the patient's sex, age and AST (P>0.05). The incidence rate of mild anemia in high expression group was significantly lower than that in low expression group (P<0.05). There was no correlation between the level of miR-609 and the incidence rate of moderate anemia (P>0.05). The number of patients with severe anemia in the miR-609 high expression group was higher than that in miR-609 low expression group (P<0.05). The incidence rate of dizziness, fatigue and fever in patients with miR-609 high expression group was significantly higher than those in patients with miR-609 low expression (P<0.05). There was no correlation between the level of miR-609 and the incidence rate of nausea in patients with thalassemia. ROC curve showed that the AUC value of microRNA-609 was 0.862, the sensitivity was 83.6%, and the specificity was 84.1%, which suggested that miR-609 had a high diagnostic value for thalassemia. Multivariate logistic regression analysis showed that MCH and mir-609 were risk factors for poor prognosis of thalassemia patients.
Conclusion: The increased level of serum miR-609 in patients with thalassemia is a risk factor for poor prognosis and can be used as a reference index for evaluating the efficacy for patients.
题目: 地中海贫血患者血清miR-609水平及其临床预后价值.
目的: 探讨地中海贫血患者血清miR-609水平及其临床预后价值.
方法: 选择自2017年 4月至 2018年 4月在本院接受治疗的地中海贫血患者127例，同时选取100例体检健康者为对照组，采用RT-PCR实验分析miR-609变化，分析miR-609与地中海贫血临床指标的关系，采用多因素Logistic回归分析评估地中海贫血预后的危险因素.
结果: 地中海贫血患者中miR-609相对表达量为3.17±0.24，显著高于对照组（P<0.05）。miR-609高表达患者ALT、Plt、MCH水平明显高于miR-609低表达患者(P＜0.05)。miR-609高表达患者Hb、sICAM-1水平明显低于miR-609低表达患者(P<0.05)。miR-609水平与患者的性别、年龄、AST无相关性(P>0.05)。miR-609高表达组患者的轻度贫血发生率明显低于miR-609低表达的患者(P<0.05)。miR-609水平与中度贫血发生率无相关性(P>0.05)。miR-609高表达组的严重贫血患者例数明显多于miR-609低表达的患者(P<0.05)。miR-609高表达组的地中海贫血患者头晕、乏力及发热发生率均明显高于miR-609低表达的患者(P<0.05)。miR-609水平与地中海贫血患者恶心发生率无相关性。ROC曲线发现，miR-609的AUC值为0.862，灵敏度为83.6%，特异度为84.1%。这提示miR-609对地中海贫血有较高的诊断价值。多因素Logistic回归分析发现，MCH 、miR-609 是地中海贫血患者预后不良危险因素.
结论: 地中海贫血患者血清miR-609水平上升，是患者的预后不良危险因素，可作为评估患者疗效的参考指标.